Number of shareholders of Upstream Bio, Inc. – NASDAQ:UPB
This article provides the title and stock ticker for Upstream Bio, Inc. (NASDAQ: UPB) and indicates it is about the number of shareholders. It appears to be a stub or a placeholder page from a financial data platform, as no actual shareholder data is presented, only navigation and copyright information.
Upstream Bio Maintained at Buy as Verekitug’s Differentiated Efficacy Supports Steady $42 Price Target
LifeSci Capital analyst Kate Dellorusso reiterated a Buy rating on Upstream Bio (UPST) with a steady $42 price target. This rating is based on the compelling efficacy data of verekitug for asthma and chronic rhinosinusitis with nasal polyps, showing reduced need for steroids/surgery and improved disease endpoints. The drug's broad impact on Type 2 inflammation biomarkers and its potential as a first-in-class TSLP inhibitor support its competitive positioning and the continued Buy recommendation.
Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference
Upstream Bio presented new data from its Phase 2 VIBRANT trial of verekitug, showing significant improvement in asthma symptom control for participants with chronic rhinosinusitis with nasal polyps (CRSwNP) and comorbid asthma. The drug also reduced nasal polyp scores and type 2 inflammatory biomarkers. These findings support verekitug's potential as a best-in-class treatment, with Phase 3 trials in CRSwNP and severe asthma planned for Q1 2027.
Upstream Bio, Inc. unveils Phase 2 VIBRANT trial data for verekitug in CRSwNP at ATS2026
Upstream Bio, Inc. presented new Phase 2 VIBRANT trial data for verekitug in chronic rhinosinusitis with nasal polyps (CRSwNP) at ATS2026. The findings included data on patients with comorbid asthma, offering important insights into the therapeutic response for this patient population. This release highlights the ongoing development of the investigational antibody therapy to address an area of significant unmet medical need.
Upstream Bio Announces Positive Phase 2 VIBRANT Trial Results for Verekitug in Chronic Rhinosinusitis with Nasal Polyps and Comorbid Asthma
Upstream Bio announced positive Phase 2 VIBRANT trial results for verekitug, demonstrating significant improvements in asthma control and nasal polyp scores in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and comorbid asthma. The treatment reduced the need for systemic corticosteroids or surgery by 83% in these patients and showed rapid, sustained reductions in inflammatory biomarkers. Upstream Bio plans to initiate Phase 3 trials for verekitug in CRSwNP and severe asthma in early 2027.
New sinus and asthma drug trial slashes steroid use, sinus surgery by 83%
Upstream Bio (NASDAQ: UPB) announced new Phase 2 VIBRANT trial data for verekitug, demonstrating significant improvements in asthma symptom control and an 83% reduction in the need for rescue systemic steroids or CRSwNP surgery for patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and comorbid asthma. The drug also showed rapid and sustained reductions in type 2 inflammatory biomarkers. The company plans to begin Phase 3 trials in CRSwNP and severe asthma in Q1 2027.
Upstream Bio Presents New Data from Phase 2 VIBRANT Trial
Upstream Bio presented new data from its Phase 2 VIBRANT trial for verekitug, demonstrating significant improvements in asthma symptom control for participants with chronic rhinosinusitis with nasal polyps (CRSwNP) and comorbid asthma. The data also showed reduced nasal polyp burden, sinonasal symptoms, and the need for steroids or surgery, alongside sustained reductions in type 2 inflammatory biomarkers. These findings support verekitug's potential as a best-in-class treatment with convenient quarterly dosing, with Phase 3 trials for CRSwNP and severe asthma planned for Q1 2027.
Analysts Offer Insights on Healthcare Companies: Icecure Medical (ICCM) and Upstream Bio, Inc. (UPB)
Two analysts have issued bullish sentiments on healthcare companies Icecure Medical (ICCM) and Upstream Bio, Inc. (UPB). Scott Henry from Alliance Global Partners maintained a Buy rating on Icecure Medical with a $1.00 price target, while Kate Dellorusso from LifeSci Capital maintained a Buy rating on Upstream Bio, Inc. with a $42.00 price target. The consensus for Icecure Medical is a "Moderate Buy" with a $2.00 target, and for Upstream Bio, Inc., it's a "Strong Buy" with a $43.75 target, indicating significant upside potential.
Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
Upstream Bio (Nasdaq: UPB) reported its Q1 2026 financial results and provided updates on its clinical programs. The company is rapidly advancing Phase 3 programs for verekitug in severe asthma and CRSwNP, anticipating FDA meetings in mid-2026 and Phase 3 initiations in Q1 2027. Upstream Bio also announced a cap on further enrollment in its Phase 2 VENTURE trial for COPD, with data now expected in H2 2027, as it plans for a high-dose quarterly regimen Phase 3 trial.
UPB Maintains Rating by Mizuho -- Price Target Lowered to $50.00
Mizuho analyst Joseph Catanzaro has maintained an "Outperform" rating for Upstream Bio (UPB) but lowered its price target to $50.00 from $51.00. This adjustment reflects a cautious outlook despite the positive rating, possibly due to concerns over near-term performance or market conditions. Upstream Bio, a biotechnology company focused on inflammatory diseases, currently has a low GF Score™ of 22 and significant insider selling, suggesting investors should proceed with caution despite the stock potentially being undervalued compared to the new price target.
Upstream Bio : Corporate Presentation May 2026 (May 13, 2026)
Upstream Bio released its corporate presentation for May 2026, outlining its focus on developing verekitug, a clinical-stage antagonist of the TSLP receptor, for severe respiratory diseases. The company plans to engage with the FDA in mid-2026 and initiate Phase 3 trials in severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) in Q1 2027, with data for its COPD trial expected in H2 2027. Upstream Bio emphasizes verekitug's potential for best-in-class efficacy with quarterly at-home dosing, supported by strong Phase 2 data in severe asthma and CRSwNP.
Press Release: Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
Upstream Bio reported its first quarter 2026 financial results and highlighted recent business achievements. The company is focused on developing therapeutics for inflammatory and immune-mediated diseases. Key updates on clinical trials and pipeline progress are expected to be included in the full report.
Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
Upstream Bio reported its first-quarter 2026 financial results, highlighting ongoing clinical development of verekitug for severe asthma, CRSwNP, and COPD. The company plans to initiate Phase 3 trials for severe asthma and CRSwNP in Q1 2027 and will cap enrollment in its Phase 2 COPD trial, with data expected in H2 2027. Upstream Bio also detailed its financial position, with $294.6 million in cash and investments, expected to fund operations through 2027.
Upstream Bio, Inc. 1Q 2026: Revenue $1.03M, EPS $(0.75) — 10-Q Summary
Upstream Bio, Inc. reported its first-quarter 2026 financial results, which included revenue of $1.03 million and a diluted EPS of $(0.75). The company's net loss increased to $(40.59) million due to higher R&D and development costs as it advanced its clinical programs. Key highlights also included progress in its clinical trials for verekitug, pipeline expansion with a new COPD trial, and strategic collaborations.
Upstream Bio reports Q1 2026 net loss $40.6M; cash and short-term investments $294.6M
Upstream Bio reported a Q1 2026 net loss of $40.6 million, an increase from $27.3 million in Q1 2025, with cash and short-term investments totaling $294.6 million. The company is advancing its lead product, verekitug, with plans for End-of-Phase 2 FDA meetings in mid-2026 and Phase 3 initiations for severe asthma and CRSwNP in Q1 2027. Research and development expenses rose due to clinical and manufacturing activities for verekitug, while general and administrative expenses also increased.
TradingKey
This page provides an overview of Upstream Bio Inc (UPB) stock on the TradingKey platform, showing its current price, market cap, and links to financial data, discussions, and analysis. It also includes general disclaimers about investment risks and the nature of the information provided by TradingKey. The content suggests that TradingKey offers tools and resources for smarter investment decisions but advises users that it does not provide financial advice.
773,148 Shares in Upstream Bio, Inc. $UPB Acquired by Pictet Asset Management Holding SA
Pictet Asset Management Holding SA has acquired a new stake of 773,148 shares in Upstream Bio, Inc. (NASDAQ:UPB), valued at approximately $20.99 million. This acquisition represents about 1.43% of the company, with other large institutional investors also increasing their holdings. Analysts currently have a "Moderate Buy" consensus rating for Upstream Bio, with an average target price of $39.00, despite the company trading near $9.40 and reporting a negative net margin.
Upstream Bio (UPB) price target decreased by 10.31% to 44.37
This article reports that Upstream Bio's (UPB) price target has been decreased by 10.31%, setting the new target at $44.37. No additional details or reasons for the change are provided in this brief update.
Upstream Bio, Inc. (NASDAQ:UPB) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Upstream Bio, Inc. (NASDAQ:UPB) has received a consensus "Moderate Buy" rating from five brokerages, with an average 12-month price target of $39.00, despite some recent downgrades. The clinical-stage biotechnology company reported a Q4 EPS miss of ($0.79) against estimates of ($0.73) and generated $0.67 million in revenue. The stock currently trades near $9.26, has a market cap of approximately $504 million, and exhibits recent weakness with its 50-day moving average below its 200-day moving average.
Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference
Upstream Bio announced two upcoming poster presentations at the ATS 2026 International Conference to share new data from its Phase 2 VIBRANT trial. The presentations will detail the clinical effect of verekitug, an antagonist for the TSLP receptor, in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and comorbid asthma, and its impact on inflammatory biomarkers. This development highlights the company's progress in targeting severe respiratory disorders with verekitug, which is also being evaluated for severe asthma and COPD.
Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference
Upstream Bio announced it will present new Phase 2 VIBRANT trial data for verekitug, an antagonist to the TSLP receptor, at the ATS 2026 International Conference. The presentations will detail verekitug's clinical effect in chronic rhinosinusitis with nasal polyps (CRSwNP) patients with comorbid asthma and its impact on nasal and blood biomarkers. This data highlights the therapy's potential for severe respiratory disorders.
Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference
Upstream Bio will present new data from its Phase 2 VIBRANT trial for verekitug at the ATS 2026 International Conference. The presentations will detail the clinical effects of verekitug, an antagonist to the thymic stromal lymphopoietin (TSLP) receptor, in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and comorbid asthma, as well as its impact on nasal and blood biomarkers. Verekitug is being developed for inflammatory diseases, with a focus on severe respiratory disorders like CRSwNP, severe asthma, and COPD.
Upstream Bio lead drug pivotal trial plan follows strong phase 2 data
This article from MSN announces that Upstream Bio is planning a pivotal trial for its lead drug. This decision follows strong results from the drug's Phase 2 clinical trial, indicating promising therapeutic potential.
Upstream Bio (UPB) price target decreased by 10.31% to 44.37
Upstream Bio (UPB) has seen its price target decreased by 10.31% to $44.37. This adjustment reflects a revised outlook on the company's valuation.
Upstream Bio (UPB) price target decreased by 10.31% to 44.37
This article reports that Upstream Bio's (UPB) price target has been decreased by 10.31%, setting the new target at $44.37. No further details are provided regarding the reasons for this change or the entities involved in adjusting the price target.
UPB Options Volatility — NASDAQ:UPB
This article from TradingView focuses on the options volatility of Upstream Bio, Inc. (NASDAQ: UPB). It provides an overview of implied volatility curves and at-the-money implied volatility across different expiration dates, aiming to help traders assess market expectations and craft options strategies. The content includes a brief description of market context and tools available on TradingView.
UPB Options Chain — NASDAQ:UPB
This page displays the options chain for Upstream Bio, Inc. (UPB) on the NASDAQ Stock Market. It provides data for call and put options, allowing users to track market movements, evaluate risks, and monitor live pricing, Greeks, and implied volatility. The tool is designed to help users build their own trading strategies.
Validating the IL-13/TSLP Axis: Upstream Bio’s Verekitug Positioned for Differentiated Asthma Efficacy and Favorable Risk–Reward
Upstream Bio’s verekitug is seen as a promising treatment for asthma, targeting the IL-13/TSLP axis, an area validated by Sanofi’s lunsekimig data. Analyst Kate Dellorusso from LifeSci Capital maintained a Buy rating and a $42.00 price target, citing verekitug's robust efficacy in the VALIANT trial and the potential for even stronger results with longer treatment. The company’s differentiated profile, funding runway, and upcoming data catalysts suggest a favorable risk-reward for investors.
Analysts Offer Insights on Healthcare Companies: Upstream Bio, Inc. (UPB) and Pfizer (PFE)
Healthcare sector companies Upstream Bio, Inc. (UPB) and Pfizer (PFE) have received analyst coverage. Truist Financial maintained a Buy rating on Upstream Bio with a $43.00 price target, suggesting a "Strong Buy" consensus from analysts and a significant upside. Bernstein analyst Courtney Breen maintained a Hold rating on Pfizer, with the Street anticipating a "Moderate Buy" consensus and a modest upside.
Piper Sandler Maintains UpStream Bio(UPB.US) With Buy Rating, Maintains Target Price $75
Piper Sandler has reiterated its Buy rating on UpStream Bio (UPB.US) and maintained its price target of $75. This continued positive outlook suggests strong confidence in the company's future performance.
Upstream Bio, Inc. (NASDAQ:UPB) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Upstream Bio, Inc. (NASDAQ:UPB) has received a "Moderate Buy" consensus recommendation from five analysts, with an average one-year price target of $39.00. Despite this, analyst views are mixed, with recent actions including both downgrades and upgrades. The company's fundamentals signal risk, including an EPS miss and negative margins, with the stock currently trading around $8.67.
Upstream Bio (NASDAQ:UPB) Rating Lowered to Sell at Wall Street Zen
Wall Street Zen has downgraded Upstream Bio (NASDAQ:UPB) from "hold" to "sell," leading to an 11.4% drop in share price. Despite this, the consensus analyst rating remains a "Moderate Buy" with an average price target of $39.00. The company recently reported a Q1 EPS of -$0.79, missing estimates, and exhibits negative profitability metrics, with analysts expecting a full-year EPS of -4.3.
Upstream Bio (NASDAQ: UPB) establishes $150M at-the-market stock program
Upstream Bio (NASDAQ: UPB) has established an at-the-market (ATM) equity program, allowing it to offer and sell up to $150 million worth of its common stock through Leerink Partners LLC. This program provides the company with flexible access to capital, enabling sales of shares over time based on market conditions. Leerink Partners will receive a commission of up to 3.0% of the gross proceeds from these sales, and neither party is obligated to sell a minimum amount of shares.
VALIANT Asthma Trial Update: What Upstream Bio’s Phase 2 Milestone Means for Investors
Upstream Bio Inc. (UPB) has completed its VALIANT Phase 2 study for verekitug (UPB-101), an injectable antibody drug aimed at reducing severe asthma attacks in adults. The trial's objective was to assess the drug's efficacy in cutting flare-ups, improving lung function, and controlling daily symptoms, while also monitoring safety. The completion of this study marks a significant milestone, and investors are now anticipating the release of data, which could influence UPB's valuation and strategic position in the competitive asthma biologics market.
Upstream Bio (NASDAQ: UPB) files ATM to raise up to $150M via Leerink
Upstream Bio (NASDAQ: UPB) has filed an at-the-market (ATM) offering to raise up to $150 million by selling shares of its common stock through Leerink Partners LLC. The biopharmaceutical company plans to use the net proceeds primarily for research and clinical development of its product candidates and for general corporate purposes. This flexible offering allows sales from time to time, with Leerink Partners receiving up to 3.0% commission on gross proceeds.
Upstream Bio (NASDAQ:UPB) Downgraded by Evercore to In-Line
Evercore has downgraded Upstream Bio (NASDAQ:UPB) from "outperform" to "in-line," setting a $15 target price which implies a 53% upside. This comes as the company missed quarterly EPS estimates and shows highly negative profitability, despite a "Moderate Buy" average rating from other analysts with a $39.00 average target price. Upstream Bio's stock trades at $9.79 with a market capitalization of $529.05 million, and its recent earnings report showed negative return on equity and net margin.
Evercore ISI cuts Upstream Bio stock rating on lack of near-term catalysts
Evercore ISI downgraded Upstream Bio (NASDAQ:UPB) to In Line from Outperform and slashed its price target due to a lack of near-term value-inflecting catalysts, ongoing financing concerns, and uncertainty surrounding its COPD trial. Despite acknowledging the long-term potential of verekitug, the firm recommends moving to the sidelines, expecting shares to trade in line with the broader biotech sector. The company is also facing significant cash burn and its stock is deemed overvalued by InvestingPro.
Evercore ISI Downgrades Upstream Bio to In Line From Outperform, Adjusts PT to $15 From $40
Evercore ISI has downgraded Upstream Bio's stock rating from Outperform to In Line and significantly reduced its price target from $40 to $15. This change indicates a less optimistic outlook on the biotechnology company, which is developing treatments for inflammatory diseases. Upstream Bio's stock (UPB) is currently trading at $8.750, having experienced a substantial year-to-date decline.
Upstream Bio, Inc. Enters At-the-Market Sales Agreement with Leerink Partners LLC for Common Stock Offering
Upstream Bio, Inc. (UPB) has entered into an At-the-Market (ATM) sales agreement with Leerink Partners LLC, allowing the company to offer and sell shares of its common stock on The Nasdaq Global Select Market. This agreement provides Upstream Bio with a flexible mechanism to raise capital for general corporate purposes, but investors should be aware of potential share dilution. The company affirms compliance with all relevant SEC regulations and will disclose further details in future filings.
According to the latest filing with the SEC, biotechnology company Upstream Bio Inc has entered into a sales agreement with Leerink Partners LLC and plans to raise up to 150 millions dollars by publicly offering common shares.
Upstream Bio Inc, a biotechnology company, has partnered with Leerink Partners LLC to raise up to $150 million through a public offering of common shares. This strategic move aims to fund the accelerated clinical development of its core pipeline drugs for inflammatory diseases and expand its operational capabilities. The collaboration highlights investor confidence in the future prospects of innovative pharmaceutical companies and will be closely watched by the market.
Upstream Bio Launches $150 Million At-The-Market Program
Upstream Bio, Inc. has initiated a $150 million "at-the-market" (ATM) equity program with Leerink Partners LLC, allowing the company to sell shares periodically to raise capital. This flexible financing option provides incremental access to funds, though it may lead to shareholder dilution. The ATM offering is supported by an effective automatic shelf registration statement and comes with a recent analyst rating of "Buy" with a $42.00 price target.
Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results
Upstream Bio has highlighted its Phase 3 development strategy for verekitug, focusing on a high-dose quarterly regimen to maximize efficacy in severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) without biomarker restriction. The company announced plans to initiate dosing in Phase 3 trials for both indications in Q1 2027, following positive Phase 2 results for verekitug. Upstream Bio also reported a strong cash position of $341.5 million at the end of 2025, expected to fund operations through 2027.
Upstream Bio (NASDAQ:UPB) Posts Earnings Results, Misses Estimates By $0.06 EPS
Upstream Bio (NASDAQ:UPB) reported its quarterly earnings, missing the consensus EPS estimate by $0.06 with a loss of ($0.79) per share, despite revenue of $0.67 million beating expectations. The company shares rose 7.9% to $10.22 following the announcement, reflecting a market capitalization of approximately $552.3 million. Analyst ratings are mixed, with a consensus of "Moderate Buy" and a price target of $45.25, while institutional investors have shown varied adjustments to their holdings.
UPB: Verekitug demonstrated strong efficacy and safety in Phase 2, with Phase 3 trials set for 2027
Verekitug, a TSLP receptor antagonist from UPB, has shown strong efficacy and safety in its Phase 2 trials for severe asthma and CRSWNP, supporting quarterly at-home dosing. The success of these trials paves the way for Phase 3 trials, which are scheduled to commence in Q1 2027, aiming at significant commercial opportunities in respiratory diseases.
Upstream Bio, Inc. unveils financial results and sets Phase 3 path for verekitug
Upstream Bio, Inc. has announced its financial results for Q4 and full year 2025 and outlined its Phase 3 development strategy for its lead asset, verekitug. This marks a crucial progression in the company's clinical pipeline. CEO Rand Sutherland has also participated in recent healthcare conferences, engaging in fireside chats to discuss the company's advancements.
Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results
Upstream Bio has highlighted its Phase 3 development strategy for verekitug, focusing on a high-dose quarterly regimen for severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), with plans to initiate dosing in Q1 2027. The company reported positive Phase 2 results for verekitug in severe asthma and CRSwNP, demonstrating significant improvements and a favorable safety profile. Upstream Bio also announced its financial results for Q4 and full year 2025, with a strong cash position of $341.5 million expected to fund operations through 2027.
Upstream Bio plans Phase 3 trials for asthma drug in Q1 2027
Upstream Bio announced plans to initiate Phase 3 clinical trials for its asthma and rhinosinusitis drug, verekitug, in Q1 2027. This follows positive Phase 2 results for severe asthma and chronic rhinosinusitis with nasal polyps, showing significant reductions in exacerbation rates and polyp scores. Despite positive clinical developments and strong analyst price targets, the company reported a net loss of $42.5 million for Q4 2025 and its stock has declined 45% over the past six months, though it maintains a strong cash position.
Upstream Bio (NASDAQ: UPB) deepens 2025 loss while推进 Phase 3 verekitug strategy
Upstream Bio reported a widened net loss of $42.5 million for Q4 2025 due to increased research and development spending on verekitug, compared to a $21.2 million loss in the prior year. Despite the larger loss, the company is making strong clinical progress, with positive Phase 2 data for verekitug in severe asthma and CRSwNP supporting its advancement into Phase 3 trials in Q1 2027. Upstream Bio maintains a strong cash position of $341.5 million, expected to fund operations through 2027.
Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results
Upstream Bio reported its Q4 and full-year 2025 financial results, highlighting a strong cash position of $341.5 million. The company is advancing its Phase 3 development strategy for verekitug, an investigational drug targeting TSLP receptor, for severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), with plans to initiate dosing in Q1 2027. This strategy is based on positive Phase 2 VALIANT trial results in severe asthma and VIBRANT trial analyses in CRSwNP, showing significant efficacy and a favorable safety profile for a high-dose quarterly regimen.
Upstream Bio, Inc.(NasdaqGS: UPB) dropped from S&P Biotechnology Select Industry Index
Upstream Bio, Inc. (NasdaqGS: UPB) has been removed from the S&P Biotechnology Select Industry Index. This news follows several recent developments for the company, including reports on its asthma and chronic rhinosinusitis with nasal polyps drug trials, and a previous addition to the NASDAQ Biotechnology Index. Analysts currently have an average target price significantly higher than its last close price.
